19 Oct 2004, 09:50 AM EDT
Msg. 170745 of 171052
Jump to msg. #  
11/04 news about 118 results it will be 1 yr since new news on 118 that we didnt already no about!!! elma nice SNAILS pace! go new boss!
By: lovingitall0
19 Oct 2004, 05:10 PM EDT
Msg. 170805 of 171052
(This msg. is a reply to 170804 by lovingitall0.)
Jump to msg. #  
Antiviral Drugs May See Shortfall

Vaccine might not be the only flu-fighting weapon in short supply this fall and winter. Some doctors and public-health experts are preparing for the possibility that supplies of antiviral drugs -- an important second line of defense against the potentially deadly disease -- also could become tight if influenza is widespread.

For complete article:

By: nick_2100
19 Oct 2004, 06:41 PM EDT
Msg. 170819 of 171052
Jump to msg. #  
ADVR where it has been and where is it going.

I have been in ADVR since 1996 Ive seen it go as high as a 1.70 or so and as low as .05 cents. Ive heard all the rumors from Bill gates getting ready to buy to the stock will be ten bucks before year end. This message board use to provide some good facts, even though there were some just looking to pump and dump. The point of my story boys and girls we need to post more meaningful post on this board so that people can walk away with a little more then what they came here with.

As far as ADVR, Im long and strong, even though for the life of me I cant seem to understand why we cant get above 10 cents. You see I am a doctor, and I know HIV is getting worse and not better and we need more drugs in the pipeline. I think ADVR's drug will turn into something some day, and those people that have been in it for a while will be rewarded.

Heres the tip of the week.......Check out IPWG it just went public. Its trading at 10 cents and this stock should be a winning. So do your DD.

(Voluntary Disclosure: Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy)

- - - - -
View Replies
By: nick_2100
19 Oct 2004, 11:02 PM EDT
Msg. 170841 of 171052
Jump to msg. #  

First off I didnt say they were testing AVR118 in China. I said using the AVR118 in china. As you may or may not know in china usually a patent means that the drug can be sold and used in china. At least thats what some collegues of mine, who have been there have told me.

As for your comment on "Makes me wonder if in fact the reason you are here is to pump IPWG - rather than offer what seems to be inaccurate "D&D" on your part re: ADVR and AVR118."

I'm simply giving a friendly stock tip, which Im sure judgeing by your astute comments you will do your research on any stock before you buy.

On your other comment;
"Or that AVR118 is not being tested for the treatment of HIV but rather the mitigation of the symptoms of the disease and the chemotherapy associated with it??"

Isnt seeing if AVR118 is good for mitigation of symptoms of the disease and the chemo associated testing the merits of the usefullness of the drug.....and therefore testing the drug in china.

There are various degrees of testing......there are testing as large as phase I/II clinical trial or as small as giving a patient a 30 day sample to see what it does...bottom line there all tests and all reportable in trying to get a drug to market.

The good thing here is we managed to talk about the company and not just posting a message 4 to 1 Red Sox.

Nice talking to you and good luck

(Voluntary Disclosure: Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy)

By: nick_2100
20 Oct 2004, 09:52 AM EDT
Msg. 170857 of 171052
Jump to msg. #  
ADVR- Short term pain or long term reward. You Decide

My reply to people like Sue and Mind is simple. Im trying to stimulate conversation on why we all come to these boards, and thats stocks talk. Ive been a member of different boards such as CNBC, yahoo ect for a while. And while I have not been a member a raging bull that long I have read the posts. In the begining there was inciteful news and people passing info on stocks that they got from doing D&D. Now once you weed out the pumper and dumpers you can see the people who have true intrests in the company. My God Sue has over 11000 posts just on this board alone, I would say see has some kind of faith in this company.

Now I dont claim to have some kind of insider info on ADVR, I have been suffering just as long as many of you, having been in it since 1996. God knows im sick of seeing a change in price of .0005 cents.

As far as the questions, I have some medical colleques in china and they told me that a patent means they can sell and use the drug. Whether thats true I have no idea. But I have to believe that the company is not sitting on its ass doing nothing. They want the drug to be successfull as possible. My god there compant revolves around the drug. My comment on FDA was a simple one. As the drug goes through testing, and I have to believe testing is being done, as the drug gets through testing and shows promise it goes to the FDA. Now that being said, drugs in the use of HIV treatment for example are brought quicker through the FDA because if need. So my comment is simple as the drug gets to the FDA the price of the company will rise.
So no insider info, just knowledge of medicine and how these things work.

The other point here is at least we are talking about stocks and passing tips around that may be usefull to people reading these forums.

Talk to you soon.


(Voluntary Disclosure: Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy)

- - - - -
View Replies
By: buckaroobanzai10
20 Oct 2004, 09:57 AM EDT
Msg. 170858 of 171052
Jump to msg. #  
Patient enrollments in the Israel trials were reported completed in a press release on 9/08/2004. That was over two months ago, and so those studies must now have been completed. I presume we should have a press release on the final results in a couple of weeks when all he results have been tabulated and analyzed, if all went well.

By: mind31
20 Oct 2004, 10:01 AM EDT
Msg. 170859 of 171052
(This msg. is a reply to 170857 by nick_2100.)
Jump to msg. #  
Nick, I have no problem with on topic posting. Here's my opinion - this company is a joke and they ARE just sitting on their ass doing nothing. The next big event is supposed to be the filing of an INDA around the first of the year. Betcha it is mid year at the earliest, that's advr time. As for selling the drug in China, I can assure you they are not. I've been here since 2000 and there is no more DD I can do - I have read all the BS. Now this is an amusement. Welcome to the forum. Whenever the INDA comes some might get off a trade aka stealing money from the new suckers.

By: mind31
20 Oct 2004, 10:06 AM EDT
Msg. 170860 of 171052
(This msg. is a reply to 170858 by buckaroobanzai10.)
Jump to msg. #  
Buck, that's 6weeks not 2 months and it is a ten week protocol. If the last patient was enrolled 9-8-04 the ten weeks end 11-16-04. Allow at LEAST 2 months for number crunching. Mid Jan 05 is my guess and if they need that data for the INDA, well - like I already said - mid year IMO.
By: lovingitall0
20 Oct 2004, 10:14 AM EDT
Msg. 170861 of 171052
(This msg. is a reply to 170825 by nick_2100.)
Jump to msg. #  
nick_2100: I must agree with you on the quality of posts here. The better contributors rarely ever post and who knows if they even read this board anymore. Once you put the few Chatty Kathy's on ignore there really isn't much left here.

After reading other stock boards one can really appreciate that this forum lacks substance and it's easy to lose interest,

There's no denying that this disastrous PPS isn't where any of us could fathom after all these years.. Yet, I feel as you do that we have a very good drug in AVR118 with an excellent history behind it and a very good future ahead of it with its applications for several indications. The frustration is that we just seem to be moving at a snail's pace and that's the conundrum.

Patience is a virtue that many don't have here anymore.

Welcome to this forum. At least you haven't been chased away yet as many others have. Believe me, I know. I've been here forever.

Again thanks for sharing the info on IPWG.


By: lovingitall0
20 Oct 2004, 10:22 AM EDT
Msg. 170865 of 171052
Jump to msg. #  
Reticulose/AVR118: Old Drug, New Hope: Used in WWII immune-system booster is now tested in AIDS fight

by Jamie Talan, Staff Writer

AN EXPERIMENTAL MEDICINE injected into U.S. military men during World War II fell into obscurity for decades and now has re-emerged in the battle against AIDS.

The drug-Substance R or Reticulose- stimulates the immune system and also interferes with viral replication, making it an important advance in pharmacology, doctors say. After more than 60 years of use, the drug is finally undergoing testing to move it through the Food and Drug Administration process.

Meanwhile, people such as Octavio A. Perez, a 32-year-old AIDS patient in Manhattan, report substantial benefit through the current drug trials. Perez spent years on a mix of AIDS drugs that caused such troublesome side effects-distressing nightmares and neuropathies of the hands and legs-that they kept him housebound. Two months ago, he began taking injections of Reticulose.

"It's really been unbelievable," said Perez. "I can walk without pain. I can sleep again." It is too early to tell whether Substance R will become a mainstream, federally approved drug for AIDS, or for any of the other conditions that might benefit from enhancing the immune system. But a small pharmaceutical company called Advanced Viral Research Corp. is betting on the drug's 67-year-old anecdotal history and has begun testing it in AIDS patients overseas. The company is planning to file several applications for its use with the Food and Drug Administration, which means that testing could move forward.

Whether the drug proves as powerful as the developers' claim, the substance stands as a lesson in endurance. Substance R was created in 1933 by a doctor who wanted to develop a medicine for his patients that would mimic the body's immune system. What Dr. Vincent Lapenta didn't know-and what no one would know for more than 60 years-is that the compound fits into a relatively new class of drugs called protein nucleic acids.

"I had never known anything to do this," said Dr. Shalom Z. Hirschman, former director of infectious diseases at Mount Sinai School of Medicine, who has left his tenured position to develop and test Reticulose.

"The lure of opening up an entire new field of therapeutics was too much," Hirschman said.

It will take years of testing before the FDA has enough data to rule on a drug's effectiveness and grant approval for use in the United States.

Ironically, Reticulose had a place in medicine for decades, listed in the Physician's Desk Reference from 1940 to 1960. At the time, Phillips Roxanne Pharmaceutical Co. was manufacturing the drug for Lapenta. In the early '60s, the company sold rights of the drug to Key Pharmaceuticals. Then, it disappeared from the PDR.

Scientists at Key Pharmaceuticals were having difficulty figuring out the chemistry of the drug-how it works-in an attempt to comply with new FDA guidelines on drug regulation passed in 1962. Scientists at Phillips Roxanne had made a slight change in the formula in 1959-bovine serum replaced horse serum as a stabilizing compound-and the newly created FDA would not allow the drug to bypass the regulation process as it had done with thousands of other drugs developed before the federal law went into effect. (The change was necessary because horse serum was linked to serum sickness.) Reticulose, now owned by Key, would have to be tested as a new drug.

Perplexed by its chemistry, the company abandoned the drug, selling rights to the substance to a Singapore firm. Within a few years, the overseas company began bankruptcy proceedings, and chances that Substance R would ever see the light of day seemed bleak.

But Bernard Friedland, a chemist at Key, would not give up on the drug.

He'd heard about the bankruptcy proceedings that began in 1972 and ended in 1985. He decided to buy the drug around 1985, and a manufacturing plant in the Bahamas that had been sitting in moth balls for more than a decade.

"I felt the drug was too important to lose," said Friedland, now 74. "I couldn't let it die." The mixture created by Lapenta in 1933 was a brew of genetic RNA material and proteins grown at certain temperatures. He used the substance on his own patients for viral infections. Others also talked about its benefits. But like all drugs of its time, the clinical success was anecdotal. There was never a serious drug trial.

When the FDA threatened its availability in the early '60s, doctors began to hoard the injectable drug for their patients. Hundreds of thousands of patients were treated for influenza A, encephalitis and other viruses during the pre-FDA decades, Friedland said.

Col. Ralph Thompson, a physician of the U.S. Medical Corps and deputy director of the Armed Forces Institute of Pathology in Washington, D.C., witnessed the same benefits in some of his charges during World War II and later: "I shall never forget the miraculous course that followed the treatment with this drug," he told colleagues at a 1960 meeting. " ... and will remember those others of my command who became ill and stricken with influenza who did not receive Reticulose therapy." He said he had also recommended its use in children with virulent encephalitis.

The substance was still a chemical mystery to Friedland when he bought the drug from the bankruptcy courts. In 1995, Hirschman was asked to take a look at the drug. Hirschman had studied nucleic acids at the National Institutes of Health in the '60s, and he had just been reading a study on nucleic acids in Science when it hit him.

"I was looking at a peptide nucleic acid, a relatively new class of substances that have powerful effects on the inflammatory process," Hirschman said. Peptide nucleic acids were first described in the early '90s. "No one would have appreciated this chemistry," Hirschman said of the early developers of the drug.

The first person he called was Friedland, who had set up a company to work on Substance R.

Hirschman's wife, Frances E. Newmann-Hirschman, a geneticist and AIDS crisis worker in Westchester, had been given samples of the drug to test. She'd been trying to find substances to fight AIDS, and she learned about Reticulose.

Her husband took the formula back to his lab. "I immediately began experimenting with it," he said. He discovered that the drug had potent interactions with the immune system, stimulating cytokines, interferon, tumor necrosis factor and other immune substances.

In addition to AIDS, the researchers believe it can also be a treatment for genital warts, human papillomavirus, herpes C virus and certain forms of arthritis. Hirschman said it could even help boost the immune system in cancer patients, a possibility that was first described by Thompson in 1960.

There are probably thousands of drugs in development that never make it into the hands of patients. But the protein nucleic acids are a new entity, opening up the possibilities of strengthening the immune system in its fight against infections, said Howard Young, section head of cellular and molecular immunology at the National Cancer Institute. He's done some genetic laboratory work with Reticulose. "There's a reasonable basis for it to work. A lot of people are studying this new class of drugs for their potential to modulate the immune system." In 1996, Hirschman's company launched the first rigorous double-blind control trials of Reticulose.

In the study, 43 AIDS patients in Barbados were randomized to receive Reticulose or a placebo injection for 60 days. This was the only treatment these patients received. At the end of the study, patients who received the drug had no signs of opportunistic infections and reported feeling more energetic, Hirschman said. Those on placebo did not report similar benefits.

Nine of the patients are still on the drug, which is taken by injection every day.

Hirschman hopes that Reticulose might be used in conjunction with conventional AIDS cocktails to strengthen the immune system.

"The more we learn about this class of drugs, the better we will be able to tailor them to treat specific diseases," Hirschman said.

July 11, 2000, Newsday

By: dirtysneakers0
20 Oct 2004, 10:30 AM EDT
Msg. 170867 of 171052
Jump to msg. #  
I've owned ADVR since it was an IPO and been adding shares the last few years. I too have hope. We finally have a CEO with experience in bringing drugs to market. With all the data official and not we have I truly believe AVR118 will be huge.

By: Ourobouros
20 Oct 2004, 10:38 AM EDT
Msg. 170870 of 171052
(This msg. is a reply to 170857 by nick_2100.)
Jump to msg. #  
" I have to believe testing is being done"

As far as I know, there is NO testing being done at this time - other than some followups and finishing of the trial in Israel. Nothing at all in regards to FDA approved tests. At all!!!

As to your "But I have to believe that the company is not sitting on its ass doing nothing." Perhaps, but that "something" in 10 years has amounted to nothing. Call them and ask what happened to all the cash spent on Globomax and why they didn't follow through on Globomax's suggestions.

As also to your "So my comment is simple as the drug gets to the FDA the price of the company will rise." - not so far. We had FDA approval for Phase II testing, they canceled it, the price went down.

Tell us some more about your philosophy as to how you think the price will go up.
- - - - -
View Replies

By: nick_2100
20 Oct 2004, 11:27 AM EDT
Msg. 170876 of 171052
(This msg. is a reply to 170870 by Ourobouros.)
Jump to msg. #  
Maybe my philosophy is ill concieved but I have still managed to make a quite abit of money over the years staying long and strong on stocks and picking up tips here and there.

As Far as your comment on:
"As far as I know, there is NO testing being done at this time - other than some followups and finishing of the trial in Israel. Nothing at all in regards to FDA approved tests. At all!!!"

Isnt a trial, testing the merits of a drug and therefore testing a drug. Maybe you been spending to much of your time pulling third molars and not keeping up with some of your journals on how research leads to treatment.

However, if your are spending most of your time pulling third molars (what is that 900 dollars a tooth these days x 4 teeth plus IV sedation fees) then your probably not concerned with a short term paper loss and still holding on to your shares in ADVR in the hopes that ADVR will still rise.

So the fact that you still visit the board means you have some intrest in the success of ADVR, and that you havent given up all hope.

I would like to hear more about the Globomax stuff, Im out of the loop on there suggestions, so if you can provide some info it would be much appreciated.

Thanks lovingit all for posting that article. Well be it old, it was nice to read.

So once again boys and girls in a short time there is info being exchanged, views being past and more talk about stocks and less about Red Sox in 7.

Thanks for all your comments and views

(Voluntary Disclosure: Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy)

- - - - -
View Replies
By: lovingitall0
20 Oct 2004, 12:34 PM EDT
Msg. 170878 of 171052
Jump to msg. #  
Asia-Pacific Region Risks 'AIDS Crisis', UNAIDS Says

20 Oct 2004

The Asia-Pacific region risks an "AIDS crisis similar in scale to Africa's" unless national governments and regional institutions "step up" efforts to fight HIV/AIDS, UNAIDS Deputy Executive Director Kathleen Cravero said on Wednesday in Manila, Philippines, AFP/Channel News Asia reports.

"We believe the economic, political and regional institutions in Asia have a great responsibility now because Asia has a window of opportunity to make sure an AIDS epidemic never takes hold ... as it did in Africa," Cravero said. The Association of Southeast Asian Nations and the Asia-Pacific Economic Cooperation forum "need to get the action much accelerated" by providing resources to individual countries, Cravero said, adding that national leaders also need to take a role in combating the spread of HIV/AIDS.

She said that regional leaders "should be promoting strong advocacy, knowledge and awareness" at their annual summits. Although the ASEAN countries have made "good progress" in the last two years, Cravero said that progress "is moving too late and too slow."

According to a study by UNAIDS and the Asian Development Bank, more than seven million HIV-positive people live in the Asia-Pacific region, 10 million more people are estimated to contract the disease by 2010 and more than 500,000 people die of AIDS-related illnesses in the region annually (AFP/Channel News Asia, 10/20).


Cravero and officials from the World Health Organization on Wednesday urged the Philippines to take HIV/AIDS prevalence in the country "more seriously," the Philippine Daily Inquirer reports (Rivera, Philippine Daily Inquirer, 10/20).

Cravero said there is low condom use, a widespread commercial sex work industry, high population mobility, high rates of sexually transmitted diseases and a lack of HIV/AIDS knowledge among the general public in the Philippines, as well as many young people engaging in "risky behavior" and injection drug users sharing needles, AFP/Channel News Asia reports.

Jean Marc Olive, chair of a U.N. group on AIDS, said that the Philippines cannot be protected by a belief that it is different from other countries. He said that condom promotion is "difficult" because President Gloria Arroyo has been hesitant to upset Roman Catholic Church officials, according to AFP/Channel News Asia (AFP/Channel News Asia, 10/20).

Stigma in Vietnam

Cravero on Monday said that the level of stigma and discrimination HIV-positive people in Vietnam face is "as great or greater" than that of any of the more than 50 countries she has visited, the AP/Long Island Newsday reports.

After visiting the Vietnamese cites of Hanoi, Ho Chi Minh City and Haiphong, Cravero lauded the government's national strategy for fighting the spread of HIV/AIDS but said that if the country does not "reverse the way people think about the disease, it could block attempts to help those infected with the virus," according to the AP/Newsday.

She urged the government to quickly implement its national strategy, with HIV-positive people taking a leading role alongside government leaders and AIDS advocacy organizations. "All too often we have national strategies that end up on shelves as very readable documents that don't mean very much on the ground," Cravero said. She added, "Now is the time -- in the coming months and the next two years -- that Vietnam must take this excellent strategy and make it real for the people" (AP/Long Island Newsday, 10/18).

Cravero also urged Vietnam to take "urgent action" to address the needs of HIV-positive women, according to an UNAIDS release. "In Vietnam, as in other countries, issues like domestic violence, lack of women's legal rights and young women's limited access to HIV education and services are fueling the epidemic," Cravero said (UNAIDS release, 10/18).

Vietnam's HIV/AIDS Policy

International AIDS advocacy workers have pushed the Vietnamese government to stop referring to the fight against HIV/AIDS as part of its "social evils" policy in order to reduce HIV/AIDS-related stigma, the AP/Newsday reports.

Most HIV infections in Vietnam occur among high-risk populations that engage in illicit drug use or commercial sex work. However, the disease could spread into the general population if left unchecked, increasing the number of HIV-positive people to one million people by 2010, according to the AP/Newsday (AP/Long Island Newsday, 10/18).

After meeting with Cravero in Hanoi on Monday, Vietnamese Deputy Prime Minister Pham Gia Khiem said that the government has established a national committee on HIV/AIDS control and hopes UNAIDS will continue to support their national strategy, which he said is one of their "top priorities," the Vietnam News Agency reports (Vietnam News Agency, 10/18).

Cravero said that the government's strategy "stands as a model for other countries in the region and the world" (UNAIDS release, 10/18). Vietnam is one of 15 countries that is set to receive funding from the United States as part of the President's Emergency Plan for AIDS Relief, a five-year, $15 billion program (Kaiser Daily HIV/AIDS Report, 10/14).


ASEAN countries

Narrower Terms:

Brunei Darussalam


Hong Kong is an important partner of ASEAN countries (Note1). With respect to individual ASEAN members, Hong Kong was the 5th largest trading partner of Singapore in 2002, the 6th largest trading partner of Cambodia (2001), the Philippines (2002) and Malaysia (2002), the 8th largest trading partner of Thailand (2001), the 10th largest trading partner of Brunei Darussalam (2001), the 11th largest trading partner of Vietnam (2001), the 12th largest trading partner of Laos (2001) and the 13th largest trading partner of Myanmar (2001) and Indonesia (2002).

5 of the ASEAN countries (i.e. Singapore, Malaysia, Thailand, the Philippines and Indonesia) were amongst the top 20 trading partners of Hong Kong in 2002. Taken as a group, ASEAN was the 3rd largest trading partner of Hong Kong during the period, after the Mainland of China and the United States

By: rickv
20 Oct 2004, 01:17 PM EDT
Msg. 170881 of 171052
(This msg. is a reply to 170876 by nick_2100.)
Jump to msg. #  
nick, some people have been with the company holding stock since the ipo in 86 such as ourobouros i have know him for a very long time electonically. and yes we have been waiting there are a lot of other companies on the pinks that have no product and have a higher pps then this company it is a white elephant for a bunch of us longs 18yrs and yes we believe that it will eventually go but i hope to be retired from some other investments rather than thinking this would be the one as i did in 86 ..

here is some history..

it is some of the info from the board without some of the non advr info.

some of july august missing i have not had the time to update.

By: Ourobouros
20 Oct 2004, 02:27 PM EDT
Msg. 170883 of 171052
(This msg. is a reply to 170876 by nick_2100.)
Jump to msg. #  
"what is that 900 dollars a tooth these days x 4 teeth plus IV sedation fees"

As for you ill advised and ignorant suggestion about my fees, I charge $120 for surgical removal of 3rd molars, and $80 for IV sedation, making it a total of $560 for all 4 including sedation.

I hope your information that you surmise about ADVR is more accurate than what you assume about MY fees.

"your probably not concerned with a short term paper loss and still holding on to your shares in ADVR in the hopes that ADVR will still rise."

I gave up on dough rising from ADVR ?profits? eons ago::

I sold ALL my ADVR shares for a $75,000 loss last year and parlayed the remaining $25,000 into some $250,000 buying HLSH at $0.49 (now at $5.00)

As far as Globomax, I suggest you go to your wellspring of ADVR knowledge for that, as I assume you gathered all your accurate original info from there in the first place. If you didn't know about Globomax...and you're trying to tell us they're using the drug in China, I'd say you were a pumper/dumper looking for short term profits, like chrome21.

One suggestion, when you come on a chat board that is occupied with shareholders (and others) who are replete with facts about the ins and outs about the company - you might try not telling THEM what is and isn't regarding facts about ADVR. You just might get caught in your own twisted facts. There's too many folks who know EVERYTHING - and I mean EVERYTHING - regarding the drug and management and very little you might inform them of.
- - - - -
View Replies